Join
Live feed
·
PRReleasevia Quantisnow
Tenaya Therapeutics Inc. logo

Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

ByQuantisnow·Wall Street's wire, on your screen.
TNYA· Tenaya Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TNYA (Tenaya Therapeutics Inc.) and more on Quantisnow.